- Home
- GLTO vs JOB Comparison
GLTO vs JOB Comparison
Compare GLTO & JOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- JOB
- Stock Information
- Founded
- GLTO 2011
- JOB 1893
- Country
- GLTO Denmark
- JOB United States
- Employees
- GLTO N/A
- JOB N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- JOB Diversified Commercial Services
- Sector
- GLTO Health Care
- JOB Consumer Discretionary
- Exchange
- GLTO Nasdaq
- JOB Nasdaq
- Market Cap
- GLTO 23.7M
- JOB 23.0M
- IPO Year
- GLTO 2020
- JOB N/A
- Fundamental
- Price
- GLTO $10.99
- JOB $0.21
- Analyst Decision
- GLTO Buy
- JOB
- Analyst Count
- GLTO 1
- JOB 0
- Target Price
- GLTO $10.00
- JOB N/A
- AVG Volume (30 Days)
- GLTO 7.6M
- JOB 270.5K
- Earning Date
- GLTO 10-31-2025
- JOB 08-13-2025
- Dividend Yield
- GLTO N/A
- JOB N/A
- EPS Growth
- GLTO N/A
- JOB N/A
- EPS
- GLTO N/A
- JOB N/A
- Revenue
- GLTO N/A
- JOB $108,752,000.00
- Revenue This Year
- GLTO N/A
- JOB $43.94
- Revenue Next Year
- GLTO N/A
- JOB N/A
- P/E Ratio
- GLTO N/A
- JOB N/A
- Revenue Growth
- GLTO N/A
- JOB N/A
- 52 Week Low
- GLTO $2.01
- JOB $0.17
- 52 Week High
- GLTO $31.70
- JOB $0.51
- Technical
- Relative Strength Index (RSI)
- GLTO 58.62
- JOB 50.24
- Support Level
- GLTO $10.53
- JOB $0.20
- Resistance Level
- GLTO $18.45
- JOB $0.21
- Average True Range (ATR)
- GLTO 2.35
- JOB 0.01
- MACD
- GLTO 0.43
- JOB -0.00
- Stochastic Oscillator
- GLTO 26.56
- JOB 29.50
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About JOB GEE Group Inc.
GEE Group Inc is a provider of specialized staffing solutions across the United States. The company's operating segment includes Industrial Staffing Services and Professional Staffing Services. It generates maximum revenue from the Professional Staffing Services segment. The company provides the following services, direct hire placement services, temporary professional services staffing in the fields of information technology, accounting, finance and office, engineering, and medical, and temporary light industrial staffing.